D Orazio & Associates Inc. Purchases 1,020 Shares of Pfizer Inc. (PFE)

D Orazio & Associates Inc. grew its position in shares of Pfizer Inc. (NYSE:PFE) by 14.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 7,862 shares of the biopharmaceutical company’s stock after buying an additional 1,020 shares during the quarter. D Orazio & Associates Inc.’s holdings in Pfizer were worth $343,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Advocacy Wealth Management Services LLC grew its holdings in shares of Pfizer by 48.2% during the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 258 shares in the last quarter. Contravisory Investment Management Inc. grew its holdings in shares of Pfizer by 182.6% during the 4th quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 745 shares in the last quarter. Vestor Capital LLC acquired a new stake in shares of Pfizer during the 3rd quarter worth $53,000. Arlington Partners LLC grew its holdings in shares of Pfizer by 64.7% during the 4th quarter. Arlington Partners LLC now owns 2,141 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 841 shares in the last quarter. Finally, Ironwood Financial llc grew its holdings in shares of Pfizer by 91.0% during the 4th quarter. Ironwood Financial llc now owns 2,229 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 1,062 shares in the last quarter. 69.49% of the stock is currently owned by institutional investors.

In other news, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $42.83, for a total transaction of $642,450.00. Following the sale, the insider now directly owns 124,994 shares of the company’s stock, valued at $5,353,493.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rady A. Johnson sold 8,700 shares of Pfizer stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $41.13, for a total value of $357,831.00. Following the sale, the insider now directly owns 59,797 shares in the company, valued at $2,459,450.61. The disclosure for this sale can be found here. Insiders have sold 332,526 shares of company stock worth $14,346,539 over the last three months. Insiders own 0.09% of the company’s stock.

PFE has been the topic of several analyst reports. Credit Suisse Group set a $45.00 target price on Pfizer and gave the stock a “neutral” rating in a report on Wednesday, December 26th. Cantor Fitzgerald set a $53.00 target price on Pfizer and gave the stock a “buy” rating in a report on Sunday, December 30th. UBS Group lowered Pfizer from a “buy” rating to a “neutral” rating in a report on Wednesday, January 23rd. ValuEngine lowered Pfizer from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Finally, Zacks Investment Research lowered Pfizer from a “hold” rating to a “sell” rating in a report on Friday, January 25th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $45.61.

NYSE:PFE opened at $39.38 on Monday. The stock has a market capitalization of $234.42 billion, a P/E ratio of 13.13, a price-to-earnings-growth ratio of 2.37 and a beta of 0.75. The company has a current ratio of 1.57, a quick ratio of 1.33 and a debt-to-equity ratio of 0.52. Pfizer Inc. has a twelve month low of $34.37 and a twelve month high of $46.47.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.01. The business had revenue of $13.98 billion for the quarter, compared to analyst estimates of $13.92 billion. Pfizer had a return on equity of 26.02% and a net margin of 20.79%. Pfizer’s revenue was up 2.0% compared to the same quarter last year. During the same period last year, the firm posted $0.62 earnings per share. Equities analysts predict that Pfizer Inc. will post 2.86 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “D Orazio & Associates Inc. Purchases 1,020 Shares of Pfizer Inc. (PFE)” was originally posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/04/22/d-orazio-associates-inc-purchases-1020-shares-of-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: How Do You Calculate Return on Equity (ROE)?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.